OTC Markets OTCPK · Biotechnology

ZyVersa Therapeutics (ZVSA)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Not covered

Ratings unavailable

$0.10-0.01 (-6.4%)Latest market snapshot · Yahoo Finance

Market cap$833,880

Cash$302,660

Quarterly burn$799,118

Pipeline assets3

Short float7.4%

Clinical portfolio

ZyVersa Therapeutics Drug Pipeline

Showing 1 of 3

Asset	Indication	Stage	Milestone	Signals ?
Cholesterol Efflux Mediator™ VAR 200	Diabetic Kidney Disease	Phase 2a	TBA	—

Continue with BioPharma ProUnlock 2 additional programs and complete development details.

Unlock Pro

Upcoming milestones

ZVSA Catalyst Timeline

1 currently tracked

TBA

Cholesterol Efflux Mediator™ VAR 200

Phase 2a

Diabetic Kidney Disease

Update

Event details

Company profile

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100 a humanized monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of numerous inflammatory diseases, with cardiometabolic conditions associated with obesity as the lead. The company has a license agreement with L&F Research LLC, and InflamaCORE, LLC. ZyVersa Therapeutics, Inc. was founded in 2014 and is based in Weston, Florida.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.